Mitrovic B, Handley K, Assarzadegan N, et al. - Researchers sought to corroborate the prognostic significance of tumor budding (TB), especially in stage II colorectal cancer (CRC), as well as to ascertain optimum thresholds for TB risk grouping. They also investigated if TB impacts responsiveness to chemotherapy. Evaluation of TB was done in CRC sections from 1575 QUASAR trial patients randomly assigned to adjuvant chemotherapy or observation. In this study, recurrence was strongly and independently predicted by TB. Comparable efficacy was demonstrated by chemotherapy in patients with higher and lower TB, thus, absolute decreases in recurrence as well as death with chemotherapy should be approximately twice as large in patients with 10+ than <10 TB counts.